Close Menu

By Adrienne Burke

A look back at the early days of the GTI invokes memories of headier times. In the first issue of GT one year ago, we published the list of companies we’d selected for our index along with the year-ago data for those few that had actually been publicly traded for at least a year already by July 31, 2000 — only 12 of the 26 had. With the exception of Affymetrix, the percent increase in stock price since the previous year for each of them was well over 100 percent.

Get the full story with
GenomeWeb Premium

Only $95 for the
first 90 days*

GenomeWeb Premium gives you:
✔ Full site access
✔ Interest-based email alerts
✔ Access to archives

Never miss another important industry story.

Try GenomeWeb Premium now.

You may already have institutional access!

Check if I qualify.

Already a GenomeWeb or 360Dx Premium member?
Login Now.

*Before your trial expires, we’ll put together a custom quote with your long-term premium options.

Not ready for premium?

Register for Free Content
You can still register for access to our free content.

SARS-CoV-2 vaccine developers are evaluating further vaccine doses as well as modified doses to keep up with new viral variants, according to CNN.

The New York Times reports that a new viral variant of concern has been identified in New York City.

In Nature this week: spatiotemporally resolved map of the human cell cycle, folding single-cell RNA sequencing into cancer drug studies, and more.

According to BBC News, the global vaccine-sharing initiative has sent its first shipment, which arrived in Ghana this week.